PCN64 Cost-Effectiveness of Pembrolizumab (KEYTRUDA®) in Combination with Chemotherapy for First-LINE Treatment of Metastatic Squamous NON-SMALL Cell LUNG Cancer (NSCLC) in France.

Authors :: Chouaid, C.
Bensimon, L.
Tardu, J.
Millier, A.
Insinga, R.
Rai, A.
Levy-Bachelot, L.
Levy, P.
Source :: Value in Health. 2020 Supplement 2, Vol. 23, pS433-S433. 1p.
Publication Year :: 2020

Subjects :: *NON-small-cell lung carcinoma
*COMBINATION drug therapy
*COST effectiveness
*PEMBROLIZUMAB
*METASTASIS

Full Text Access

Tools